ValiRx plc Cash Flow Conversion Efficiency
ValiRx plc cash flow conversion efficiency. Based on the latest financial reports, ValiRx plc (VAL) has a cash flow conversion efficiency ratio of -0.179x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (£-700.73K ≈ $-941.02K USD) by net assets (£3.92 Million ≈ $5.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ValiRx plc (2001–2024)
Cash flow conversion efficiency of ValiRx plc from 2001 to 2024. This chart illustrates how ValiRx plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ValiRx plc stock quote for real-time trading data and today's change.
ValiRx plc Cash Flow Conversion Ratio Explained
ValiRx plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ValiRx plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ValiRx plc ranked by their cash flow conversion efficiency. Also see VAL market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jupiter Neurosciences, Inc. Common Stock
NASDAQ:JUNS
|
6.271x |
|
Devernois SA
PA:ALDEV
|
0.102x |
|
Fuller Smith & Turner
LSE:FSTA
|
0.093x |
|
Glacier Lake Resources Inc
V:GLI
|
0.010x |
|
Zonetail Inc
V:ZONE
|
0.041x |
|
Commander Resources Ltd
V:CMD
|
-0.123x |
|
Rincon Resources Ltd
AU:RCR
|
-0.029x |
|
Kmc Properties ASA
OL:KMCP
|
0.039x |
Annual Cash Flow Conversion Efficiency for ValiRx plc (2001–2024)
The table below shows the annual cash flow conversion efficiency of ValiRx plc from 2001 to 2024. Review free cash flow generation of ValiRx plc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | £3.92 Million ≈ $5.26 Million |
£-1.58 Million ≈ $-2.13 Million |
-0.405x | +33.68% |
| 2023-12-31 | £2.90 Million ≈ $3.90 Million |
£-1.77 Million ≈ $-2.38 Million |
-0.610x | -36.39% |
| 2022-12-31 | £3.83 Million ≈ $5.14 Million |
£-1.71 Million ≈ $-2.30 Million |
-0.447x | -21.21% |
| 2021-12-31 | £3.41 Million ≈ $4.59 Million |
£-1.26 Million ≈ $-1.69 Million |
-0.369x | +8.12% |
| 2020-12-31 | £4.76 Million ≈ $6.39 Million |
£-1.91 Million ≈ $-2.57 Million |
-0.402x | +33.42% |
| 2019-12-31 | £2.22 Million ≈ $2.99 Million |
£-1.34 Million ≈ $-1.80 Million |
-0.604x | +45.45% |
| 2018-12-31 | £3.03 Million ≈ $4.07 Million |
£-3.35 Million ≈ $-4.50 Million |
-1.106x | -48.34% |
| 2017-12-31 | £3.15 Million ≈ $4.23 Million |
£-2.35 Million ≈ $-3.16 Million |
-0.746x | +58.08% |
| 2016-12-31 | £2.37 Million ≈ $3.18 Million |
£-4.22 Million ≈ $-5.66 Million |
-1.779x | -211.40% |
| 2015-12-31 | £4.53 Million ≈ $6.09 Million |
£-2.59 Million ≈ $-3.48 Million |
-0.571x | +47.02% |
| 2014-12-31 | £2.79 Million ≈ $3.74 Million |
£-3.01 Million ≈ $-4.04 Million |
-1.079x | -68.52% |
| 2013-12-31 | £3.23 Million ≈ $4.34 Million |
£-2.07 Million ≈ $-2.78 Million |
-0.640x | -62.79% |
| 2012-12-31 | £5.04 Million ≈ $6.76 Million |
£-1.98 Million ≈ $-2.66 Million |
-0.393x | -19.06% |
| 2011-12-31 | £4.42 Million ≈ $5.94 Million |
£-1.46 Million ≈ $-1.96 Million |
-0.330x | -32.96% |
| 2010-12-31 | £2.00 Million ≈ $2.68 Million |
£-496.00K ≈ $-666.08K |
-0.248x | +75.67% |
| 2009-12-31 | £907.00K ≈ $1.22 Million |
£-926.00K ≈ $-1.24 Million |
-1.021x | -76.42% |
| 2008-12-31 | £1.37 Million ≈ $1.84 Million |
£-794.00K ≈ $-1.07 Million |
-0.579x | -15.19% |
| 2007-12-31 | £1.67 Million ≈ $2.24 Million |
£-839.00K ≈ $-1.13 Million |
-0.502x | -2848.55% |
| 2006-12-31 | £2.69 Million ≈ $3.61 Million |
£-45.77K ≈ $-61.46K |
-0.017x | +95.01% |
| 2006-03-31 | £161.00K ≈ $216.21K |
£-55.00K ≈ $-73.86K |
-0.342x | -210.08% |
| 2005-12-31 | £-203.00K ≈ $-272.61K |
£-63.00K ≈ $-84.60K |
0.310x | -90.48% |
| 2004-12-31 | £-69.00K ≈ $-92.66K |
£-225.00K ≈ $-302.15K |
3.261x | +195.24% |
| 2003-12-31 | £67.00K ≈ $89.97K |
£74.00K ≈ $99.38K |
1.104x | +108.81% |
| 2002-12-31 | £-141.00K ≈ $-189.35K |
£1.77 Million ≈ $2.37 Million |
-12.539x | -759.53% |
| 2001-12-31 | £1.00 Million ≈ $1.35 Million |
£1.91 Million ≈ $2.56 Million |
1.901x | -- |
About ValiRx plc
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stag… Read more